share_log

維亞生物：於二零二四年一月十八日舉行的股東特別大會的投票結果；及委任非執行董事

VIVA BIOTECH: POLL RESULTS OF THE EGM HELD ON JANUARY 18, 2024; AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR

香港交易所 ·  Jan 18 05:22
Summary by Moomoo AI
維亞生物於2024年1月18日舉行的股東特別大會上，通過了有關維亞上海第一期及第二期股權激勵計劃的普通決議案，並委任王暉先生為非執行董事。該股權激勵計劃將授予合資格激勵對象期權，以認購維亞上海股份。所有決議案均獲超過50%的贊成票，正式通過。股東特別大會的投票無任何限制，並由卓佳證券登記有限公司監票。王暉先生的任期自當日起計為期三年。
維亞生物於2024年1月18日舉行的股東特別大會上，通過了有關維亞上海第一期及第二期股權激勵計劃的普通決議案，並委任王暉先生為非執行董事。該股權激勵計劃將授予合資格激勵對象期權，以認購維亞上海股份。所有決議案均獲超過50%的贊成票，正式通過。股東特別大會的投票無任何限制，並由卓佳證券登記有限公司監票。王暉先生的任期自當日起計為期三年。
At the Extraordinary General Meeting held on 18 January 2024, VIA Bio adopted the Ordinary Resolution on the Phase I and Phase II Share Incentive Schemes of VIA Shanghai and appointed Mr. Wang Fai as a Non-Executive Director. The Equity Incentive Scheme will grant eligible incentive objects options to subscribe for shares in VIA Shanghai. All resolutions received more than 50% approval and were formally approved. Voting at the Extraordinary General Meeting is unrestricted and monitored by Jujia Securities Registration Limited. The term of office of Mr. Wang Fui is three years from that date.
At the Extraordinary General Meeting held on 18 January 2024, VIA Bio adopted the Ordinary Resolution on the Phase I and Phase II Share Incentive Schemes of VIA Shanghai and appointed Mr. Wang Fai as a Non-Executive Director. The Equity Incentive Scheme will grant eligible incentive objects options to subscribe for shares in VIA Shanghai. All resolutions received more than 50% approval and were formally approved. Voting at the Extraordinary General Meeting is unrestricted and monitored by Jujia Securities Registration Limited. The term of office of Mr. Wang Fui is three years from that date.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more